Resistance is often ascribed to either resistant mutations such as BTK and PLCγ2 reported in IR MCL and chronic lymphocytic leukaemia or adaptive mechanisms, including amplification of alternative signalling pathways and altered cell states19, 20. The gene discussed is PLCG2; the disease is mantle cell lymphoma.